26 June 2025 - Today, Astellas Pharma Canada announced that Xtandi (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the treatment of patients with non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk of metastasis. 

This decision means Xtandi is now publicly reimbursed in Ontario for all of its approved prostate cancer indications.

Read Astellas press release